The new Clinical Trial Application for the conduct of a Phase I/II study of RVU120 (SEL120) in patients with solid tumors submitted by Ryvu Therapeutics S.A.
Three Posters on SEL24/MEN1703 including Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial to be published at American Society of Hematology (ASH) Annual Meeting